Dendreon to cut 150 jobs as cancer vaccine sales drop again

   Date:2013/11/13     Source:

 Biotechnology company Dendreon Corp said it would reduce annual costs by $125 million and cut about 150 jobs in a new round of restructuring, as it struggles to boost sales of its flagship cancer vaccine.

Dendreon's net product revenue, reflecting Provenge sales, fell 13 percent to $68 million in the third quarter ended September 30.

Dendreon had cut 600 jobs and closed its New Jersey manufacturing facility in a restructuring in July last year to save about $150 million annually.

Dendreon said it would have about 820 employees at the end of the restructuring, down from more than 2,000 at its peak.

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号